Skip to main content
SpringerLink
Log in

Pharmacoepidemiology in Cardiorenal Medicine

  • Chapter
  • First Online:
Textbook of Cardiorenal Medicine

  • 585 Accesses

Abstract

Cardiorenal syndrome (CRS) describes the phenomenon of joint dysfunction of the heart and kidneys and occurs when the acute or chronic dysfunction of one organ subsequently triggers acute or chronic dysfunction in the other. The majority of patients with chronic kidney disease (CKD) succumb to cardiovascular complications. Many pharmacologic agents influence the natural history of both CKD and heart disease through a variety of mechanisms. In this chapter, we provide an overview of pharmacological therapies available for patients with heart failure (HF) and adaptations employed for patients with CRS, as well as common themes contributing to the drugs’ underutilization. Therapies utilized for the management of HF may include angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta adrenergic receptor blockers, mineralocorticoid receptor antagonists (MRAs), diuretics, statins, digoxin, and sodium-glucose transport protein 2 (SGLT2) inhibitors. Many of these classes (or particular drugs within the class) have dosing guidelines specifically based on the degree of renal impairment. Although these drugs have been associated with decreased cardiovascular morbidity and mortality, they remain underutilized. Several factors prevent patients from receiving optimal drug therapy, some of which may be attributable to pill burden, poor comprehension and affordability, risk of side effects (which often increase with concomitant kidney dysfunction), and contextual issues faced by the prescribing physician.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–78. https://doi.org/10.1161/CIR.0000000000000664. PubMed PMID: 30852913.

    Article  PubMed  Google Scholar 

  2. McCullough PA, Afzal A, Kale P. Goal-directed heart failure care in patients with chronic kidney disease and end-stage renal disease. JACC Heart Fail. 2016;4(8):662–3. https://doi.org/10.1016/j.jchf.2016.03.014. PubMed PMID: 27289405.

    Article  PubMed  Google Scholar 

  3. House AA. Management of heart failure in advancing CKD: core curriculum 2018. Am J Kidney Dis. 2018;72(2):284–95. https://doi.org/10.1053/j.ajkd.2017.12.006. PubMed PMID: 29478868.

    Article  PubMed  Google Scholar 

  4. Centers for Disease Control and Prevention. National chronic kidney disease fact sheet. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2017.

    Google Scholar 

  5. McCullough PA. Interface between renal disease and cardiovascular disease. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1909–30.

    Google Scholar 

  6. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 Acc/Aha/Aapa/Abc/Acpm/Ags/Apha/Ash/Aspc/Nma/Pcna guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115.

    CAS  PubMed  Google Scholar 

  7. Bennett WM. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia, PA: American College of Physicians; 2007, 272 p.

    Google Scholar 

  8. Members Writing Committee, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, Guidelines American College of Cardiology Foundation/American Heart Association Task Force on Practice. 2013 Accf/Aha guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–327.

    Google Scholar 

  9. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW, Guidelines American College of Cardiology Foundation/American Heart Association Task Force on Practice. 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362–425.

    Article  PubMed  Google Scholar 

  10. Members Writing Committee, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 Acc/Aha/Hfsa focused update on new pharmacological therapy for heart failure: an update of the 2013 Accf/Aha guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282–93.

    Google Scholar 

  11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 Acc/Aha/Hfsa Focused Update of the 2013 Accf/Aha Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776–803.

    Article  PubMed  Google Scholar 

  12. von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl. 2001;19:S33–40.

    Article  Google Scholar 

  13. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. Aha/Acc/Aacvpr/Aapa/Abc/Acpm/Ada/Ags/Apha/Aspc/Nla/Pcna guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e143.

    PubMed  Google Scholar 

  14. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Guidelines American College of Cardiology/American Heart Association Task Force on Practice. 2013 Acc/Aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.

    Article  PubMed  Google Scholar 

  15. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.;2020.

    Google Scholar 

  16. Farxiga [package insert]. Princeton, NJ: Bristol Meyers Squibb Company. Wilmington, DE: AstraZeneca Pharmaceuticals LP;2019.

    Google Scholar 

  17. Jardiance [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.;2016.

    Google Scholar 

  18. Herman LL, Bashir K. Angiotensin converting enzyme inhibitors (ACEI). Treasure Island, FL: StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK431051/.

    Google Scholar 

  19. Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, Wolf RA. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 1999;33(5):1174–81. PubMed PMID: 10193713.

    Article  CAS  PubMed  Google Scholar 

  20. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008;4:CD003823. https://doi.org/10.1002/14651858.CD003823.pub2. Review. PubMed PMID: 18843651.

    Article  Google Scholar 

  21. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115. https://doi.org/10.1161/HYP.0000000000000065. Review. Erratum in: Hypertension.2018;71(6):e140-e144. PubMed PMID: 29133356.

    Article  CAS  PubMed  Google Scholar 

  22. Bian B, Kelton CM, Guo JJ, Wigle PR. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm. 2010;16(9):671–9. PubMed PMID: 21067253.

    PubMed  Google Scholar 

  23. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008;4:CD003822. https://doi.org/10.1002/14651858.CD003822.pub2. Review. PubMed PMID: 18843650.

    Article  Google Scholar 

  24. Desai RJ, Ashton CM, Deswal A, Morgan RO, Mehta HB, Chen H, Aparasu RR, Johnson ML. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012;21(3):233–40. https://doi.org/10.1002/pds.2175. PubMed PMID: 21786364.

    Article  CAS  PubMed  Google Scholar 

  25. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772–6. PubMed PMID:13678870.

    Article  CAS  PubMed  Google Scholar 

  26. Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: results from Val-HeFT. J Card Fail. 2003;9(3):164–71. PubMed PMID: 12815565.

    Article  CAS  PubMed  Google Scholar 

  27. Murphy DP, Drawz PE, Foley RN. Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States. J Am Soc Nephrol. 2019;30(7):1314–21. https://doi.org/10.1681/ASN.2018100971. PubMed PMID: 31167823; PubMed Central PMCID: PMC6622408.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Centers for Disease Control and Prevention. Chronic kidney disease surveillance system—United States. website. http://www.cdc.gov/ckd.

  29. Kim CS. Pharmacologic management of the cardio-renal syndrome. Electrol Blood Press. 2013;11(1):17–23. https://doi.org/10.5049/EBP.2013.11.1.17.

    Article  CAS  Google Scholar 

  30. Chang TI, Yang J, Freeman JV, Hlatky MA, Go AS. Effectiveness of β-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease. J Card Fail. 2013;19(3):176–82. https://doi.org/10.1016/j.cardfail.2013.01.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70:1905–13.

    Article  CAS  PubMed  Google Scholar 

  32. Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65(5):565–70. Review. PubMed PMID: 21125979.

    Article  PubMed  Google Scholar 

  33. Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327. https://doi.org/10.1161/CIR.0b013e31829e8776. PubMed PMID: 23741058.

    Article  Google Scholar 

  34. Tomiyama H, Yamashina A. Beta-blockers in the management of hypertension and/or chronic kidney disease. Int J Hypertens. 2014;2014:919256. https://doi.org/10.1155/2014/919256.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Scott JH, Dunn RJ. Physiology, aldosterone. Treasure Island, FL: StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK470339/.

    Google Scholar 

  36. Sica DA. Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist Debakey Cardiovasc J. 2015;11(4):235–9. https://doi.org/10.14797/mdcj-11-4-235.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019;96:302. https://doi.org/10.1016/j.kint.2019.02.030. pii: S0085-2538(19)30300-X. Review. PubMed PMID: 31133455.

    Article  CAS  PubMed  Google Scholar 

  38. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. Erratum in: N Engl J Med. 2003;348(22):2271. PubMed PMID: 12668699.

    Article  CAS  PubMed  Google Scholar 

  39. Jonsson A, Norberg H, Bergdahl E, Lindmark K. Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population. Cardiovasc Ther. 2018;36(5):e12459. https://doi.org/10.1111/1755-5922.12459.

    Article  CAS  PubMed  Google Scholar 

  40. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    Article  CAS  PubMed  Google Scholar 

  41. Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Baylor Univ Med Cent). 2004;17(2):217–20. https://doi.org/10.1080/08998280.2004.11927973.

    Article  Google Scholar 

  42. Manolis AA, Manolis TA, Melita H, Manolis AS. Eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men’s issue? Curr Hypertens Rep. 2019;21(3):22. https://doi.org/10.1007/s11906-019-0924-0. Review. PubMed PMID: 30826898.

    Article  CAS  PubMed  Google Scholar 

  43. Blankenburg M, Fett A, Eisenring S, et al. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. BMC Nephrol. 2019;20:171. https://doi.org/10.1186/s12882-019-1348-4.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153:1021–8. https://doi.org/10.1016/j.ahj.2007.03.012.

    Article  PubMed  Google Scholar 

  45. Ellison DH. Mechanistic insights into loop diuretic responsiveness in heart failure. Clin J Am Soc Nephrol. 2019;14(5):650–2. https://doi.org/10.2215/CJN.03590319. PubMed PMID: 31064772; PubMed Central PMCID: PMC6500933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. National Kidney Foundation. NKF KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. 2004. https://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bp/guide_12.htm.

  47. Khan YH, Sarriff A, Adnan AS, Khan AH, Mallhi TH. Chronic kidney disease, fluid overload and diuretics: a complicated triangle. PLoS One. 2016;11(7):e0159335. https://doi.org/10.1371/journal.pone.0159335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Täger T, Fröhlich H, Grundtvig M, Seiz M, Schellberg D, Goode K, Kazmi S, Hole T, Katus HA, Atar D, Cleland JGF, Agewall S, Clark AL, Frankenstein L. Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - a multicenter propensity score matched analysis. Int J Cardiol. 2019;289:83–90. https://doi.org/10.1016/j.ijcard.2019.01.109. PubMed PMID: 30827731.

    Article  PubMed  Google Scholar 

  49. Akbari P, Khorasani-Zadeh A. Thiazide diuretics. Treasure Island, FL: StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK532918/.

    Google Scholar 

  50. Alon US. The effects of diuretics on mineral and bone metabolism. Pediatr Endocrinol Rev. 2018;15(4):291–7.

    PubMed  Google Scholar 

  51. Casu G, Merella P. Diuretic therapy in heart failure - current approaches. Eur Cardiol. 2015;10(1):42–7. https://doi.org/10.15420/ecr.2015.10.01.42.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26(2):183–9. PubMed PMID: 6503136.

    Article  CAS  PubMed  Google Scholar 

  53. Brater DC. Update in diuretic therapy: clinical pharmacology. Semin Nephrol. 2011;31(6):483–94. https://doi.org/10.1016/j.semnephrol.2011.09.003. Review. PubMed PMID: 22099505.

    Article  CAS  PubMed  Google Scholar 

  54. Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, De Regt J, Spapen HD. Statins and the kidney: friend or foe? Blood Purif. 2017;43(1-3):91–6. https://doi.org/10.1159/000453577. Review. PubMed PMID: 27951534.

    Article  CAS  PubMed  Google Scholar 

  55. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Sao Paulo Med J. 2015;133:541–2.

    Article  Google Scholar 

  56. Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA. Statins in stroke prevention: present and future. Curr Pharm Des. 2016;22:4638–44.

    Article  CAS  PubMed  Google Scholar 

  57. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:259–305.

    Article  Google Scholar 

  58. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28. https://doi.org/10.1016/j.ahj.2018.12.007. Review. PubMed PMID: 30716508.

    Article  CAS  PubMed  Google Scholar 

  59. Chou R, Dana T, Blazina I, et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2016. Evidence syntheses, No. 139. Table 1, Statin Dosing and ACC/AHA Classification of Intensity. https://www.ncbi.nlm.nih.gov/books/NBK396417/table/ch1.t1/.

    Google Scholar 

  60. Mefford MT, Rosenson RS, Deng L, Tanner RM, Bittner V, Safford MM, Coll B, Mues KE, Monda KL, Muntner P. Trends in statin use among US adults with chronic kidney disease, 1999-2014. J Am Heart Assoc. 2019;8(2):e010640. https://doi.org/10.1161/JAHA.118.010640. PubMed PMID: 30651020; PubMed Central PMCID: PMC6497356.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Currie GM, Wheat JM, Kiat H. Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc Med J. 2011;5:130–5. https://doi.org/10.2174/1874192401105010130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Malik A, Masson R, Singh S, Wu WC, Packer M, Pitt B, Waagstein F, Morgan CJ, Allman RM, Fonarow GC, Ahmed A. Digoxin discontinuation and outcomes in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;74(5):617–27. https://doi.org/10.1016/j.jacc.2019.05.064. PubMed PMID: 31370952.

    Article  CAS  PubMed  Google Scholar 

  63. MacLeod-Glover N, Mink M, Yarema M, Chuang R. Digoxin toxicity: case for retiring its use in elderly patients? Can Fam Physician. 2016;62(3):223–8.

    PubMed  PubMed Central  Google Scholar 

  64. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.

    PubMed  Google Scholar 

  65. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(5):525–33. https://doi.org/10.1161/CIRCOUTCOMES.111.000079. PubMed PMID: 24021697.

    Article  PubMed  Google Scholar 

  66. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73–9. https://doi.org/10.1097/MED.0000000000000311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Ndefo UA, Anidiobi NO, Basheer E, Eaton AT. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015;40(6):364–8.

    PubMed  PubMed Central  Google Scholar 

  68. Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes. 2018;9(12):252–7. https://doi.org/10.4239/wjd.v9.i12.252.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27–35. https://doi.org/10.1016/S2213-8587(19)30384-5. PubMed PMID: 31862149.

    Article  CAS  PubMed  Google Scholar 

  70. Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99. https://doi.org/10.1186/s12933-019-0903-4.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271–305. https://doi.org/10.1007/164_2016_76. Review. PubMed PMID: 27830348.

    Article  CAS  PubMed  Google Scholar 

  72. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–96. https://doi.org/10.2215/CJN.00290109. PubMed PMID: 19423571; PubMed Central PMCID: PMC2689877.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Parker K, Nikam M, Jayanti A, Mitra S. Medication burden in CKD-5D: impact of dialysis modality and setting. Clin Kidney J. 2014;7(6):557–61. https://doi.org/10.1093/ckj/sfu091.

    Article  PubMed  PubMed Central  Google Scholar 

  74. St Peter WL, Wazny LD, Patel UD. New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management. Curr Opin Nephrol Hypertens. 2013;22:656–62.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Wilson IB, Schoen C, Neuman P, et al. Physician-patient communication about prescription medication nonadherence: a 50-state study of America’s seniors. J Gen Intern Med. 2007;22(1):6–12. https://doi.org/10.1007/s11606-006-0093-0.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161(6):400–7. https://doi.org/10.7326/M13-2942. PubMed PMID: 25222387.

    Article  PubMed  Google Scholar 

  77. Hauptman PJ, Goff ZD, Vidic A, Chibnall JT, Bleske BE. Variability in retail pricing of generic drugs for heart failure. JAMA Intern Med. 2017;177(1):126–8. https://doi.org/10.1001/jamainternmed.2016.6955.

    Article  PubMed  Google Scholar 

  78. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234–42.

    Article  CAS  PubMed  Google Scholar 

  79. Borghi C, Veronesi M. Cough and ACE inhibitors: the truth beyond placebo. Clin Pharmacol Ther. 2019;105(3):550–2. https://doi.org/10.1002/cpt.1040. PubMed PMID: 29468656.

    Article  PubMed  Google Scholar 

  80. Tseng DS, Kwong J, Rezvani F, Coates AO. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med. 2010;123(2):183.e11–5. https://doi.org/10.1016/j.amjmed.2009.06.032. PubMed PMID: 20103031.

    Article  CAS  Google Scholar 

  81. Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5(3):744–9. https://doi.org/10.1016/j.jaip.2017.02.018.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Sica DA. Angiotensin-converting enzyme inhibitors side effects—physiologic and non-physiologic considerations. J Clin Hypertens (Greenwich). 2004;6(7):410–6. Review. PubMed PMID: 15249800.

    Article  CAS  Google Scholar 

  83. Sica DS. Pharmacotherapy in congestive heart failure: ACE inhibitors and anemia in congestive heart failure. Congest Heart Fail. 2000;6(6):330–2. PubMed PMID: 12189339.

    Article  CAS  PubMed  Google Scholar 

  84. Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–39. https://doi.org/10.1093/eurheartj/ehy182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Pergolizzi JV Jr, Coluzzi F, Colucci RD, Olsson H, LeQuang JA, Al-Saadi J, Magnusson P. Statins and muscle pain. Expert Rev Clin Pharmacol. 2020;13:299. https://doi.org/10.1080/17512433.2020.1734451.

    Article  CAS  PubMed  Google Scholar 

  86. Toth PP, Patti AM, Giglio RV, et al. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018;18(3):157–73. https://doi.org/10.1007/s40256-017-0259-7.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124(2):328–50. https://doi.org/10.1161/CIRCRESAHA.118.312782. Review. PubMed PMID: 30653440.

    Article  CAS  PubMed  Google Scholar 

  88. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. https://doi.org/10.1038/s41598-017-02733-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764–9. https://doi.org/10.7326/M19-0085. Review. PubMed PMID: 31060053.

    Article  PubMed  Google Scholar 

  90. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, O’Neal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104(8):3077–87. https://doi.org/10.1210/jc.2019-00139. PubMed PMID: 30835263.

    Article  PubMed  Google Scholar 

  91. Collard D, Brouwer TF, Peters RJG, Vogt L, van den Born BH. Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus. Hypertension. 2018;72(6):1337–44. https://doi.org/10.1161/HYPERTENSIONAHA.118.11944. PubMed PMID: 30571235.

    Article  CAS  PubMed  Google Scholar 

  92. Steinman MA, Dimaano L, Peterson CA, Heidenreich PA, Knight SJ, Fung KZ, Kaboli PJ. Reasons for not prescribing guideline-recommended medications to adults with heart failure. Med Care. 2013;51(10):901–7. https://doi.org/10.1097/MLR.0b013e3182a3e525. PubMed PMID: 23969589; PubMed Central PMCID: PMC3806480.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med. 2017;84(12):934–42. https://doi.org/10.3949/ccjm.84a.17056. Review. PubMed PMID: 29244647.

    Article  PubMed  Google Scholar 

  94. Evans M, Palaka E, Furuland H, Bennett H, Linde C, Qin L, McEwan P, Bakhai A. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrol. 2019;20(1):31. https://doi.org/10.1186/s12882-019-1228-y. PubMed PMID: 30704421.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37(9):677–92. https://doi.org/10.1007/s40264-014-0196-1. Review. PubMed PMID: 25047526.

    Article  CAS  PubMed  Google Scholar 

  96. Campese V. Electrophysiological and clinical consequences of hyperkalemia. Kidney Int Suppl. 2016;6(1):16–9. https://doi.org/10.1016/j.kisu.2016.01.003. PubMed PMID: 30675415.

    Article  Google Scholar 

  97. Diercks DB. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004;27(2):153–60. https://doi.org/10.1016/j.jemermeg.2004.04.006. PubMed PMID: 15261358.

    Article  PubMed  Google Scholar 

  98. Ingelfinger JR. A new era for the treatment of hyperkalemia? N Engl J Med. 2015;372(3):275–7. https://doi.org/10.1056/NEJMe1414112. PubMed PMID: 25415806.

    Article  PubMed  Google Scholar 

  99. Pun PH. Serum potassium levels and risk of sudden cardiac death among patients with chronic kidney disease and significant coronary artery disease. Kidney Int Rep. 2017;2(6):1122–31. https://doi.org/10.1016/j.ekir.2017.07.001. PubMed PMID: 29270520.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Genovesi S. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant. 2009;24(8):2529–36. https://doi.org/10.1093/ndt/gfp104. PubMed PMID: 19293137.

    Article  PubMed  Google Scholar 

  101. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085–95. https://doi.org/10.2215/CJN.00340118. Review. PubMed PMID: 29934432; PubMed Central PMCID: PMC6032582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Keller F, Hann A. Clinical pharmacodynamics: principles of drug response and alterations in kidney disease. Clin J Am Soc Nephrol. 2018;13(9):1413–20. https://doi.org/10.2215/CJN.10960917. PubMed PMID: 29769182; PubMed Central PMCID: PMC6140566.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Singhania G, Ejaz AA, McCullough PA, Kluger AY, Balamuthusamy S, Dass B, Singhania N, Agarwal A. Continuation of chronic heart failure therapies during heart failure hospitalization - a review. Rev Cardiovasc Med. 2019;20(3):111–20. https://doi.org/10.31083/j.rcm.2019.03.562. Review. PubMed PMID: 31601085.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor Heart and Vascular Institute, Dallas, TX, USA

    Kristen M. Tecson

  2. Baylor University Medical Center, Dallas, TX, USA

    Scott S. Shafiei

Authors
  1. Kristen M. Tecson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott S. Shafiei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristen M. Tecson .

Editor information

Editors and Affiliations

  1. Baylor University Medical Center, Texas A&M University, Dallas, TX, USA

    Peter A. McCullough

  2. Director, Department of Nephrology Dialysis and Transplantation, International Renal Research Institute (IRRIV), Ospedale San Bortolo Vicenza, Vicenza, Italy

    Claudio Ronco

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tecson, K.M., Shafiei, S.S. (2021). Pharmacoepidemiology in Cardiorenal Medicine. In: McCullough, P.A., Ronco, C. (eds) Textbook of Cardiorenal Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-57460-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-57460-4_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-57459-8

  • Online ISBN: 978-3-030-57460-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation